Our team
Board of Directors
Luis Sánchez-Lafuente
Chairman
Former Chief Executive Officer and co-owner of Laboratorios Gelos, SA. President of AB Biotics, SA


Carles Domènech
Executive chairman
Executive Chairman, CSO and co-Founder of Ability Pharmaceuticals, SL


José Manuel Valadés
General secretary
Lawyer, partner and founder of the law firm Alliant Abogados


Miquel Àngel Bonachera
Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in biochemistry and MBA.
BSc/MSc in biochemistry and MBA.


Sergi Audivert
Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in food technology and MBA.
BSc/MSc in food technology and MBA.


Sara Secall
Operating Partner & Life Sciences Investment Director of Inveready Asset Management


Santiago Descarrega
Venture Capital Partner at Fitalent (grup Everis)


LATEST NEWS
11.05.2021
Press Release
Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe + info
28.12.2020
Press Release
The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020
Press Release
The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
05.11.2020
Press Release
AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020
Press Release
AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020
Press Release
ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020
Press Release
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020
Press Release
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019
Press Release
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info